A case of multiple metastatic low-grade endometrial stromal sarcoma arising from an ovarian endometriotic lesion

Uterine sarcomas are rare tumors that are characterized by rapid progression and a poor prognosis. Histologically, they are classified as leiomyosarcomas, endometrial stromal sarco- mas (ESSs) and mixed mesodermal tumors. ESSs are rare ne- oplasms that comprise approximately 0.2% of all uterine ma- lignancies and about 10-15% of all uterine sarcomas. 1 In par- ticular, the development of ESS in endometriotic lesions is very rarely reported. Such extrauterine ESSs can develop in the ovary, fallopian tube, pelvic cavity, colon and retroperito- neum. 2 Since ovarian ESS is so rare, very little is known about its pathogenesis. However, at least in some cases, it may be a metastatic tumor that originates from a uterine tumor, perhaps years after a hysterectomy was performed to remove the primary tumor. Here we describe a case of low-grade ESS with multiple metastasis that arose from an ovarian endometriotic lesion af- ter hysterectomy. CASE REPORT A 50-year-old gravida 4, para 3, abortion 1 woman presented with lower back pain that had lasted for 1 month. In April 2000, the patient underwent total abdominal hysterectomy due to uterine myoma in our hospital. The uterus was sent for pathohistological analysis. Histologically, the myoma ap- peared to be an adenomyomtous polyp. In September 2008, the patient returned to our hospital due to back pains. Com- puted tomography (CT) showed a necrotic solid mass meas- uring 7 cm in diameter in the left adnexa, a para-aortic solid mass lesion, and left renal vein and inferior vena cava throm- bosis, which was suggestive of nodal metastasis, probably pel- vic nodal metastasis (Fig. 1). We performed a ultrasound - guided biopsy of the para-aortic solid mass. Histological anal- ysis revealed a spindle cell tumor with malignant features, in- cluding high cellularity and abnormal mitotic figures. The da- ta from the tumor marker studies are as follows: cancer anti- gen (CA)-125, 118.4 IU/ml; CA 19-9, 38.7 IU/ml; carcinoem- bryonic antigen (CEA), 1.8 ng/ml; alpha-foetoprotein (AFP), 1.6 ng/ml. The complete blood cell count data are as follows: hemoglobin, 12.6 g/dl; white blood cell count, 8,900/mm 3; platelet count, 273,000/mm3. Other examinations, including urinalysis, liver function tests and renal function tests, re- vealed no abnormalities. Esophagoduodenoscopy revealed re- flux esophagitis and gastropathy. Colonoscopy detected hem- orrhoids and a 0.2 cm diameter polyp 50 cm from the anal verge. Histologically, the tumor appeared to be a tubular adenoma. On the basis of these findings, we performed an ex- ploratory laparotomy followed by a tumor debulking pro- cedure. The surgical procedure consisted of a bilateral sal- pingoophorectomy, an appendectomy, an omentum biopsy, a posterior cul-de-sac area biopsy and cytology. In the left ad- nexa, a 6×5 cm-sized mass was detected. It was composed of a solid and a cystic portion. It adhered to the posterior cul-de- sac and was accidentally ruptured during the operation. In the right adnexa, multiple small nodules approximately 1cm in Ovarian endometrial stromal sarcoma 123 Fig. 1. Computed tomography showing a necrotic solid mass meas- urin g 7 cm in d iam eter o n th e left ad n e xa (B ), a h ug e pa ra -ao rtic solid mass lesion, and left renal vein and inferior vena cava throm- bosis, which is suggestive of nodal metastasis (A, C). (A, B) axial image, (C) coronal image. Fig. 2. Gross findings of the left ovary. The cut surface shows a dif- fuse dark reddish hemorrhagic lesion containing a solid focal yel- lowish lesion. Fig. 3. Microscopic findings of the left ovary. The sections of the left ovary exhibit perivascular whorling proliferation of plump and spindle cells with a scanty cytoplasm and indistinct cell borders (A, hema- toxylin-eosin, ×200; B, hematox- ylin-eosin, ×400). Immunohisto- chemical staining analyses revealed that the neoplastic cells were im- munoreactive to CD10 (C, ×400) and ER (D, ×400). diameter were detected. In addition, the right adnexa had ad- hered to the omentum. A hard nodule about 2-3 cm in diame- ter was detected at the right infundibulopelvic ligament. The para-aortic lymph node was enlarged to a size of 10×8×5 cm and had invaded the aorta, inferior vena cava and common iliac vessels. Consequently, it was not possible to perform an en bloc excision of the para-aortic mass. The rectum con- tained numerous nodules up to 0.5 cm in diameter. The ap- pendix, liver surface and diaphragm were normal. Grossly, the left ovary measured 8.0×6.5×4.0 cm in size and weighed 83 gm. The external surface was pale pink to whitish and smooth. Upon sectioning, the cut surface showed a dif- fuse dark reddish hemorrhagic lesion containing a focal yel- lowish solid lesion (Fig. 2). The right ovary had a smooth sur- face and a unilocular cyst with hemorrhaging. The cul-de-sac mass measured 1.3×0.5 cm in size. The omentum exhibited multiple small nodules. Microscopically, the left ovary exhibited perivascular whorl- ing proliferation of plump spindle cells with scanty cytoplasm and indistinct cell borders. There were many irregular small J Gynecol Oncol Vol. 20, No. 2:122-125, 2009 Joo Yeon Kim, et al. 124 Table 1. Result of immunohistochemical examination Ab Endometrial stromal sarcoma CD 10 + Vimentin + Ki-67 + ER 3+ PR 3+ SMA − CD10: cluster of differentiation 10, ER: estrogen receptor, PR: pro- gesterone receptor, SMA: smooth muscle actin Table 2.Microscopic features of ovarian endometrioid stromal sar- coma Diffuse growth pattern Extraovarian intravascular growth Small round or oval cells with scanty cytoplasm Pericellular reticulum Fibromatous component Associated endometriosis vessels around the tumor cells and hemorrhage was con- spicuous (Fig. 3B). Benign endometrial glands and sparse stroma were observed at the periphery of the tumor (Fig. 3A). Mitotic figures 4-5 per 10 high power field (HPF) were ob- served. The right ovary exhibited pure ESS nodules with lym- phovascular invasion. However, there were no endometriotic foci in the right ovary. The cul-de-sac mass exhibited ESS with endometrial glands. The omentum exhibited metastatic ESS. Immunohistochemical staining revealed that the neoplastic cells were immunoreactive to antibodies specific for cluster of differentiation 10 (CD10) (Fig. 3C), Vimentin, Ki-67, estro- gen receptor (ER) (Fig. 3D), progesterone receptor (PR) (Table 1). To treat this ESS, which had arisen from the ovarian endo- metriotic lesion and exhibited multiple metastasis, chemo- radiation therapy was planned. The patient is currently under- going a course of chemoradiation therapy and hormonal ther- apy with progestins. Thus, the para-aortic area was irradiated with 5,040 cGY, and 60 mg/m 2 cisplatin plus 4,000 mg/m2 ifosfamide is now being administered a total of 6 cycles, at three week intervals. In December 2008, the radiation therapy was completed and the patient had received her fifth che- motherapy. A follow-up CT showed interval improvement of the nodal metastasis in the pelvic and para-aortic spaces. Moreover, the venous thrombosis of the inferior vena cava and the left renal vein was no longer apparent.

The development of ESS in foci of endometriosis is ex- tremely rare and differentiating such tumors from other tu- mors, such as myogenic, vascular, hemopoietic or epithelial origin tumors, may be difficult. 3 The etiology of ESS is unknown. However, there are some reports that suggest that ESS is an endometriosis-associated de novo tumor derived from submesothelial pluripotential mullerian cells. 4 Ovarian sex cord stromal tumors with a predominant spindle cell com- ponent, Sertoli-Leydig cell tumors and primary mesenchymal tumors such as gastrointestinal stromal tumors (GISTs) are also important differential diagnostic considerations. 3,5,6 Malignant transformation is an infrequent complication of endometriosis. Of the extrauterine ESSs, the ovary is the primary site in 76% of cases, while extragonadal sites accounts for the remaining 24%. 5 The microscopic differential diagnosis of ovarian ESS includes three major categories of neoplasms: namely, other pure sarcomas; malignant mesodermal mixed tumors, partic- ularly mesodermal adenosarcoma; and sex cord-stromal tumors. The major diagnostic features that are helpful in iden- tifying the endometrioid stromal nature of an ovarian tumor are listed in Table 2. The possible origins of ESS of the ovary are endometriosis of the usual type and pure stromal endome- triosis (foci of gland-free endometrial stroma in the ovary). 7,8 Similar neoplasms have arisen in association with endome- triosis in various other locations. 9 It is also possible that some ESSs of the ovary arise directly from ovarian stromal cells that have undergone neometaplasia into endometrial stromal-type cells. In this case, the left ovary showed gradual progression of usual endometriotic foci to low grade ESS (Fig. 3A) with mul- tiple metastatic nodules in the right ovary, cul-de-sac and omentum. ESS has traditionally been divided into two categories, namely, low-grade and high-grade stromal sarcoma. In most studies, ESS comprises less than 20% of uterine sarcomas and most are low-grade stromal sarcomas (LGSSs). 10 The mitotic activity of LGSSs is low, namely, less than 10/10 HPF. High-grade stromal sarcomas (HGSSs), on the other hand, are tumors with mitotic activities that generally exceed 10/10 HPF, although some HGSSs can also have mitotic activities below 10/10 HPF. 10 Histological analyses of extrauterine extraovarian ESS reveal infiltrative or tongue-like multinodular growth patterns. Cytological atypia is minimal to mild, and mitotic figures are infrequently seen, namely, up to 5 mitotic figures per 10 HPF. Vascular and lymphatic invasion by the tumor is occasionally present. 11 Characteristic immunohistochemical features of ESS include reactivity to antibodies specific for Vimentin, ER and CD10, and nonreactivity to antibodies against CD117, smooth mus- cle actin (SMA) and cytokeratin (CK). A recent study has shown that among the cases of ESS that were examined, all cases were immunoreactive to anti-CD10 (5/5 cases) and an- ti-progesterone receptor (10/10 cases) antibody, most re- acted with anti-estrogen receptor antibody (9/11 cases), 5/9 and 3/7 were focally positive for smooth muscle actin and des- min, respectively, and all were negative for CD34 (0/7 cas- Ovarian endometrial stromal sarcoma 125 es).11 While it is now widely accepted that diffuse CD10 im- munoreactivity is a very useful positive predictive marker of ESS, evaluating CD10 immunoreactivity alone is often not helpful for differentiating ESS from its mimics. With regard to the progesterone receptor, while ESSs show high sensitivity to antibodies against this antigen, this immunostain is less specific for differentiating ESS from other mesenchymal tumors. Therefore, a panel of immunohistochemical stains that comprise CD10, estrogen receptor and CD34 may be more helpful for diagnosing extrauterine extraovarian ESS. To the best of our knowledge, there is one previous report that describes ovarian ESSs, namely, that of Young et al. 6, who reviewed 23 cases of ESSs of the ovary. The patients' ages ranged from 20 to 76 years (average, 54 years). The most com- mon presenting symptom was abdominal swelling or pain. In 12 cases, the tumors were unilateral, while in 11 cases they in- volved both ovaries. Four of the tumors were Stage I, nine were Stage II, eight were Stage III and two were Stage IV be- cause of the presence of pulmonary metastases. In nine of the cases, there was a prior, synchronous or subsequent ESS of the uterus. Nineteen tumors with HPF less than 10 MF/10 HPF were classified as low grade and the remaining four tu- mors with 12 to 30 MF/10 HPF were designated as high grade. Only two of the 19 patients with low-grade tumors are known to have died of their disease, and nine of those whose tumor had spread beyond the ovary at the time of presentation were alive one or more years postoperatively. However, three of the four patients with high-grade tumors died of their disease within 4 years. Surgery has always been described as the most effective treatment for uterine sarcomas. Total abdominal hyster- ectomy with bilateral salpingo-oophorectomy is considered to be the standard treatment for early stage low-grade ESS. 12 Whenever possible, complete tumor clearance should be attempted. The options of adjuvant therapy following surgery include radiotherapy, chemotherapy, hormonal therapy and observation. 12-14 The indications and the roles of adjuvant therapies remain controversial. Low grade ESSs are mostly steroid receptor-positive tumors, which means hormonal therapy with progestins, aromatase inhibitors (third gen- eration) and gonadotropin-releasing hormone (GnRH) ana- logues is effective. Progesterone is considered to be a useful form of therapy for residual or recurring low grade ESS. LGSSs usually grow slowly and tend to recur many years after the ini- tial surgery. The pelvic cavity followed by the vagina and lung are the main sites of metastases. In conclusion, the behavior of ESSs of the ovary is similar to that of their uterine counterparts, with the degree of mitotic activity being of major prognostic significance. The prognosis of patients with low-grade tumors is considerably better than that of patients with other pure ovarian sarcomas. 15 This case illustrates the findings of low-grade ESS with multiple meta- stasis arising from an ovarian endometriotic lesion.

1. Diesing D, Cordes T , Finas D, Loning M, Mayer K, Diedrich K, et al. Endometrial stromal sarcomas: a retrospective analysis of 11 patients. Anticancer Res 2006; 26(1B): 655-61. 2. Yokosuka K, Kumagai M, Aiba S. Low-grade endometrial stro- mal sarcoma recurring after 9 years. South Med J 2002; 95: 1196-200. 3. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrick- son MR. Primary extrauterine endometrial stromal neoplasms: a clinicopathologic study of 20 cases and a review of the literature. Int J Gynecol Pathol 1993; 12: 282-96. 4. Baiocchi G, Kavanagh JJ, Wharton JT . Endometrioid stromal sarcomas arising from ovarian and extraovarian endometriosis: report of two cases and review of the literature. Gynecol Oncol 1990; 36: 147-51. 5 . M o urra N , T iret E, P arc Y , d e Sa in t-M aur P , P a rc R, F lejo u JF . Endometrial stromal sarcoma of the rectosigmoid colon arising in extragonadal endometriosis and revealed by portal vein thrombosis. Arch Pathol Lab Med 2001; 125: 1088-90. 6. Young RH, Prat J, Scully RE. Endometrioid stromal sarcomas of the ovary: a clinicopathologic analysis of 23 cases. Cancer 1984; 53: 1143-55. 7. Hughesdon PE. The origin and development of benign stroma- tosis of the ovary. J Obstet Gynaecol Br Commonw 1972; 79: 348-59. 8. Hughesdon PE. The endometrial identity of benign stromatosis of the ovary and its relation to other forms of endometriosis. J Pathol 1976; 119: 201-9. 9. Mostoufizadeh M, Scully RE. Malignant tumors arising in en- dometriosis. Clin Obstet Gynecol 1980; 23: 951-63. 1 0 . Z a l o u d e k C , H e d r i c k s o n M R . M e s e n c h y m a l t u m o r s o f t h e uterus. In: Kurman RJ, editor. Blaustein's pathology of the fe- male genital tract. New York: Springer; 2002. p.586-90. 11. Kim L, Choi SJ, Park IS, Han JY , Kim JM, Chu YC, et al. Endometrial stromal sarcoma of the small bowel. Ann Diagn Pathol 2008; 12: 128-33. 1 2 . Le u n e n M , B r e u g e lm a n s M , D e S u t t e r P , B o u r g a in C , A m y JJ. Low-grade endometrial stromal sarcoma treated with the ar- omatase inhibitor letrozole. Gynecol Oncol 2004; 95: 769-71. 13. Paillocher N, Lortholary A, Abadie-Lacourtoisie S, Morand C, Verriele V , Catala L, et al. Low-grade endometrial stromal sar- coma: contribution of hormone therapy and etoposide. J Gynecol Obstet Biol Reprod 2005; 34: 41-6. 14. Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 2004; 104(5 Pt 2): 1182-4. 15. Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E , M a y e r h o f e r S , e t a l . P r o g n o s t i c p a r a m e t e r s i n e n d o m e t r i a l stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 2001; 81: 160-5.